Patents by Inventor Vincent Stroobant
Vincent Stroobant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8492342Abstract: The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.Type: GrantFiled: June 19, 2008Date of Patent: July 23, 2013Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Rescherche MedicaleInventors: Faten El Hage, Vincent Stroobant, Pierre G. Coulie, Fathia Mami-Chouaib
-
Publication number: 20110112282Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, in which each compound is adapted to occupy the binding site of human IDO, which comprises a large hydrophobic pocket A and a second, proximal hydrophobic pocket B, the compound comprising at least one of the following elements: (i) a large hydrophobic fragment to substantially fill pocket A in the binding site of human IDO; (ii) an atom that can coordinate to the heme iron of human IDO, (iii) a positively charged group that can form a salt-bridge with the heme 7-propionate of the human IDO; (iv) a negatively charged group that can form a salt-bridge with Arg231 of the human IDO; (v) a hydrophobic group that can form van der Waals interactions with pocket B; and (vi) one or more substituents that can hydrogen bond to Ser167 and to Gly262, and as IDO inhibitors and their therapeutic use, eg in the treatment of cancer.Type: ApplicationFiled: April 15, 2009Publication date: May 12, 2011Inventors: Ute Roehrig, Loay Awad, Olivier Michelin, Benoit Van Den Eynde, Luc Pilotte, Vincent Stroobant, Pierre Larrieu
-
Publication number: 20100184700Abstract: The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.Type: ApplicationFiled: June 19, 2008Publication date: July 22, 2010Inventors: Faten El Hage, Vincent Stroobant, Pierre G. Coulie, Fathia Mami-Chouaib
-
Patent number: 7351409Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: January 7, 2004Date of Patent: April 1, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Patent number: 7311914Abstract: The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.Type: GrantFiled: August 13, 2002Date of Patent: December 25, 2007Assignee: Ludwig Institute for Cancer ResearchInventors: Yi Zhang, Vincent Stroobant, Vincenzo Russo, Thierry Boon-Falleur, Pierre van der Bruggen
-
Patent number: 7252825Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: GrantFiled: June 12, 2002Date of Patent: August 7, 2007Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit BrusselInventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
-
Publication number: 20040185033Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: ApplicationFiled: January 7, 2004Publication date: September 23, 2004Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Patent number: 6716809Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.Type: GrantFiled: September 15, 1999Date of Patent: April 6, 2004Assignee: Ludwig Institute for Cancer ResearchInventors: Erwin Schultz, Pascal Chaux, Jacques van Snick, Bernard Lethe, Thierry Boon-Fallaur, Pierre van der Bruggan, Vincent Stroobant, Kris Thielemans, Jurgen Corthals, Carlo Heirman
-
Patent number: 6710172Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.Type: GrantFiled: July 30, 2001Date of Patent: March 23, 2004Assignee: Ludwig Institute For Cancer ResearchInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Publication number: 20040033541Abstract: The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.Type: ApplicationFiled: August 13, 2002Publication date: February 19, 2004Inventors: Yi Zhang, Vincent Stroobant, Vincenzo Russo, Thierry Boon-Falleur, Pierre van der Bruggen
-
Publication number: 20030170792Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: ApplicationFiled: June 12, 2002Publication date: September 11, 2003Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Corthals
-
Patent number: 6531451Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: April 9, 1999Date of Patent: March 11, 2003Assignees: Ludwig Institute for Cancer Research, Universite Catholique de LouvainInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
-
Publication number: 20020164654Abstract: The invention provides antigenic peptides derived from MAGE-A1 polypeptides and presented by HLA-B35 and HLA-B44 molecules. Antigenic peptides derived from MAGE-A3 polypeptides and presented by HLA-B35 molecules also are provided. Methods for diagnosis and treatment which involve the polypeptides also are provided.Type: ApplicationFiled: January 19, 2001Publication date: November 7, 2002Inventors: Rosalie Luiten, Thierry Boon-Falleur, Pierre Van der Bruggen, Vincent Stroobant, Nathalie Demotte, Erwin Schultz
-
Patent number: 6426217Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: GrantFiled: October 27, 2000Date of Patent: July 30, 2002Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit BrusselInventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
-
Patent number: 6407063Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: October 2, 1998Date of Patent: June 18, 2002Assignees: Ludwig Institute for Cancer Research, Universite Catholique de LouvainInventors: Rosalie Luiten, Marie-Therese Duffour, Nathalie Demotte, Pierre van der Bruggan, Guy Cornelius, Vincent Stroobant, Christophe Lurquin, Thierry Boon-Falleur
-
Patent number: 6369211Abstract: The invention describes the HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: GrantFiled: July 7, 1999Date of Patent: April 9, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen
-
Patent number: 6291430Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: GrantFiled: October 5, 1998Date of Patent: September 18, 2001Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit BrusselInventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
-
Patent number: 5965535Abstract: The invention describes the HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4.sup.+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.Type: GrantFiled: September 12, 1997Date of Patent: October 12, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen